ELENI ANASTASIADOU

Curriculum Vitae – Eleni Anastasiadou
Part I – General Information

Full Name: Eleni Anastasiadou
Spoken Languages: Greek, Italian, English
ORCID: https://orcid.org/0000-0003-0212-6734

Part II – Education

Master’s degree in Biology (M.Sc): 2004, Sapienza University of Rome.
Thesis title: “Role of Epstein-Barr virus in the pathogenesis of primary effusion lymphomas”.

Ph.D. in Experimental Medicine (XX cycle): 2009, Department of Experimental Medicine, Sapienza University of Rome.
Ph.D. Thesis title: “Regulation of Epstein-Barr virus latency in B cell lymphomas of varied differentiation stages”.

Specialization in Microbiology and Virology: 2014, Faculty of Medicine and Dentistry, Sapienza University of Rome.
Dissertation title: “Epstein-Barr virus infection and dysregulation of cellular microRNA: Implications for diagnosis and therapy of plasma cell neoplasms”.

National Scientific Eligibility (ASN): 2019, Sector 06/A2, Associate Professor. Valid 10/05/2019–10/05/2028.

National Scientific Eligibility (ASN): 2019, Sector 06/N1, Associate Professor. Valid 06/09/2019–06/09/2028.

National Scientific Eligibility (ASN): 2024, Sector 06/A2, Full Professor. Valid 10/03/2025–10/03/2037.

2023–2025: Certification obtained for “QUID – Qualità e Innovazione nella Didattica”.

Part III – Appointments

2009–2010: Postdoctoral Fellow from Institut Pasteur Cenci Bolognetti, Department of Experimental Medicine, Sapienza University, Rome.

2010–2014: Research Fellow, Department of Experimental Medicine, Sapienza University, Rome.

2014–2018: Senior Research Associate, Department of Pathology / Institute for RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.

2018–2020: Research Fellow, Department of Experimental Medicine, Sapienza University, Rome.

2021–09/10/2022: Assistant Professor (non-tenured), RTDA MED/46, Department of Experimental Medicine, Sapienza University, Rome.

2021–present: Scientific Expert, REPRISE Register (MIUR) for evaluation of basic research projects.

10/10/2022–present: Assistant Professor (tenure-track), RTDB MEDS-02/A (ex MED/04), Department of Clinical and Molecular Medicine (DCMM), Sapienza University, Rome.

Part IV – Teaching Experience and Supervision
National

Docent and invited lecturer in multiple courses at Sapienza University (2011–present), including:
– Molecular Virology (Master II level);
– Medical Scientific Methodology (Medicine and Surgery, English track);
– Physiopathology and General Pathology (Nursing and Physiotherapy Schools);
– PhD-level courses in Translational Medicine and Oncology;
– Member of PhD Academic Boards (2021–present).

Supervision:
– Co-supervisor or supervisor of multiple Master’s and PhD theses (2018–present).

International

– 2018: Docent at Harvard Medical School, course on non-coding RNAs and cancer.
– 2014–2018: Co-supervisor of graduate students at Harvard Medical School.
– 2022-2025: International PhD Examiner, University of Granada, Spain, University of Cape Town, South Africa.

Part V – Society Memberships, Awards, Honors

(Member lists and awards unchanged; included for completeness.)
– Member of AACR, SSICA, SIPMeT, SIRTEPS, Harvard Catalyst, etc.
– ITWIIN 2021 Award, special mention for international patent WO2019232160.

Part VI – Patents and Media Coverage

2019: International patent WO2019232160 – RNA-Aided Immunotherapeutics (Anastasiadou, Trivedi, Slack).

2018–2024: National and international media coverage for publications in Leukemia, Clinical Cancer Research, and Blood.

Part VII – Presentations (Selected)

(Oral presentations, invited lectures, and posters at international meetings including AACR, Keystone, RNA World, EBV Symposium, Harvard Medical School, etc.)

Part VIII – Funding Information (Selected)

Roles as PI, Co-PI, or Investigator in national and international projects funded by AIRC, PRIN, LILT, Sapienza University, Harvard Medical School, and others (2004–2027).

Part IX – Research Activities (Short Version)

My research focuses on the molecular mechanisms by which microRNAs and Epstein-Barr virus (EBV) regulate immune checkpoints, oncogenic pathways, and tumor immunogenicity in EBV-associated B-cell lymphomas, diffuse large B-cell lymphoma (DLBCL), and ovarian cancer. The aim is to translate mechanistic insights into new diagnostic and therapeutic strategies.

a) EBV–oncogene–miRNA interactions in B-cell lymphomas:
Identified how EBV proteins (EBNA2, LMP1) regulate oncogenes and miRNAs relevant to lymphoma development.

b) EBV and miRNAs in multiple myeloma:
Demonstrated EBV-mediated induction of miR-21 in myeloma cells.

c) EBV/EBNA2 regulation of immune checkpoints:
Discovered EBNA2-driven PD-L1 upregulation via miR-34a suppression; contributed to the development of 3D microfluidic immunogenicity models and a related international patent.

d) miRNA-based therapeutics:
Showed preclinical and early clinical effectiveness of anti-miR-155 (cobomarsen) in DLBCL.

e) miR-200c in ovarian cancer:
Identified a dual onco-suppressive role and therapeutic implications of miR-200c-3p in ovarian cancer.

f) miR-24–ICOSL axis in EBV-positive lymphomas:
Demonstrated that EBNA2 induces miR-24 to reduce ICOSL, promoting immune evasion (Blood 2024).

The list of all publications can be found at:
https://www.ncbi.nlm.nih.gov/myncbi/eleni.anastasiadou.2/bibliography/pu...